Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy

Table 2 Recurrence-free survival for the total cohort and by tumor subtype

Treatment group	Overall (N = 721, P = 0.45)		HR (n = 143, P = NA)		HER2-amplified (n = 312, P = 0.42)		TN (n = 216, P = 0.59)
Treatment group	No. of patients	5-yr RFS (%)	No. of patients	5-yr RFS (%)	No. of patients	5-yr RFS (%)	No. of patients	5-yr RFS (%)
A no T	56	93 (86–100)		–^a		–^a	22	86 (73–100)
A + T	367	91 (88–94)	124	92 (87–97)	55	89 (80–98)	170	92 (87–96)
AT + HER2	227	93 (89–96)		–^a	220	93 (90–97)		–^a
PC	71	85 (78–94)	11	80 (58–100)	33	91 (81–100)	21	85 (72–100)

Abbreviations: HR Hormone receptor, TN Triple-negative breast cancer, A no T Adriamycin-based therapy alone, A + T Adriamycin plus taxane, AT + HER2 HER2-targeted therapy, PC provider choice
^aMissing cells < 10 patients

ISSN: 1465-542X